These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11518065)

  • 21. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.
    Butterweck V; Christoffel V; Nahrstedt A; Petereit F; Spengler B; Winterhoff H
    Life Sci; 2003 Jun; 73(5):627-39. PubMed ID: 12770617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG).
    Dimpfel W; Schober F; Mannel M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():30-5. PubMed ID: 9684945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort.
    Kumar V; Mdzinarishvili A; Kiewert C; Abbruscato T; Bickel U; van der Schyf CJ; Klein J
    J Pharmacol Sci; 2006 Sep; 102(1):47-54. PubMed ID: 16936454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperforin as a possible antidepressant component of hypericum extracts.
    Chatterjee SS; Bhattacharya SK; Wonnemann M; Singer A; Müller WE
    Life Sci; 1998; 63(6):499-510. PubMed ID: 9718074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.
    Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of the antidepressant activity of Hypericum perforatum on animal models.
    Gambarana C; Tolu PL; Masi F; Rinaldi M; Giachetti D; Morazzoni P; De Montis MG
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S42-4. PubMed ID: 11518074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
    Obach RS
    J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperforin: more than an antidepressant bioactive compound?
    Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
    Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
    Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA
    Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining hyperforin and hypericin content in eight brands of St. John's wort.
    de los Reyes GC; Koda RT
    Am J Health Syst Pharm; 2002 Mar; 59(6):545-7. PubMed ID: 11908248
    [No Abstract]   [Full Text] [Related]  

  • 31. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man.
    Franklin M; Cowen PJ
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S29-37. PubMed ID: 11518072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
    Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
    J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of St John's wort in depression : what is known?
    Butterweck V
    CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulation of hippocampal acetylcholine release by hyperforin, a constituent of St. John's Wort.
    Kiewert C; Buchholzer ML; Hartmann J; Chatterjee SS; Klein J
    Neurosci Lett; 2004 Jul; 364(3):195-8. PubMed ID: 15196674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. St. John's Wort: is it effective and harmless?
    Biron CR
    RDH; 1999 Jun; 19(6):74-6. PubMed ID: 10895712
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models.
    Gobbi M; Moia M; Funicello M; Riva A; Morazzoni P; Mennini T
    Planta Med; 2004 Jul; 70(7):680-2. PubMed ID: 15303261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. St John's wort: Prozac from the plant kingdom.
    Di Carlo G; Borrelli F; Ernst E; Izzo AA
    Trends Pharmacol Sci; 2001 Jun; 22(6):292-7. PubMed ID: 11395157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo neurotransmitter release in the locus coeruleus--effects of hyperforin, inescapable shock and fear.
    Philippu A
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S111-5. PubMed ID: 11518058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
    Laakmann G; Schüle C; Baghai T; Kieser M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.
    Schempp CM; Winghofer B; Lüdtke R; Simon-Haarhaus B; Schöpf E; Simon JC
    Br J Dermatol; 2000 May; 142(5):979-84. PubMed ID: 10809859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.